Kling is developing a growing pipeline of drug candidates that recognize novel targets and epitopes. Our ability to identify functional antibodies and their targets is facilitated by a well-optimized process of target identification paired with experienced antibody engeneering to maximize the therapeutic potential of our discoveries.
Fully human antibodies derived from elite responders and engineered for optimal efficacy
Derived from a melanoma survivor, KBA1412 binds a unique epitope on CD9. Currently undergoing Phase I study for solid tumor indications.
Derived from AML survivor, recognizes an AML specific CD43 glycoepitope
Identified from multiple AML survivors, binds to ectopic antigen on AML cells.
Derived from Lynch syndrome/colon carcinoma responder, binds to DSG2 (Desmoglein)
Derived from Lynch syndrome/colon carcinoma survivor, binds to novel truncated form of CDH1 (E-Cadherin)
Stable B cell clones identified with Kling-Select and primed for directed evolution against emerging variants with Kling-Evolve